Drugs / TAA06
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05190185 | Jun 2021 → Dec 2023 | cancer | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAA06 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05190185 ↗ |
| Modality | Cell therapy | “TAA06 injection is a CAR T injection targeting B7-H3.” NCT05190185 ↗ |